OKYO Pharma's Recent Presentation Highlights
In a noteworthy development for the field of ophthalmology, OKYO Pharma Limited (NASDAQ: OKYO) has caught the attention of the medical community by announcing its participation in a significant conference focused on ocular health. As a clinical-stage biopharmaceutical company, OKYO specializes in pioneering treatments for neuropathic corneal pain (NCP) and inflammatory dry eye disease (DED), addressing critical needs in a market that is in desperate need of effective therapies.
Conference Presentation Overview
During the upcoming 10th International Tear Film & Ocular Surface Society (TFOS) Conference, slated to take place in Venice, Italy, OKYO Pharma will present their findings on the Efficacy and Safety of their novel treatment, OK-101. This is particularly exciting as OK-101 is currently being evaluated for its potential to relieve symptoms of DED, a condition that affects millions globally.
Noteworthy Presentation Details
The presentation will be detailed by Dr. Raj Patil, the company's Chief Scientific Officer, during a special Poster Session III on November 2, 2024. This offers an excellent opportunity for participants at the conference to engage with the latest research findings regarding this condition and to understand the innovative approaches being taken by OKYO Pharma.
Significance of Dry Eye Disease
Dry Eye Disease is prevalent among countless individuals, with studies estimating that around 49 million people in the U.S. alone experience this debilitating issue. The causes of DED are complex and multifactorial, influenced by not just environmental factors but also physiological ones. This complexity has made diagnosis and treatment challenging for many healthcare professionals, emphasizing the need for more effective solutions.
Understanding Neuropathic Corneal Pain
NCP, a critical area of focus for OKYO, is characterized by persistent pain in and around the eye. Understanding that this condition may stem from nerve damage or inflammation is vital as it portrays the urgency for alternative and effective treatment options. As of now, there are no FDA-approved therapies specifically targeting this painful condition, making clinical trials and innovative therapies like OK-101 imperative.
Role of OK-101 in Treating Ocular Conditions
OK-101 is set apart in its approach as it acts on the ChemR23 receptor present in immune cells, potentially modulating the inflammatory response seen in conditions like DED and NCP. This receptor-targeted therapy marks a hopeful advancement in therapeutic options, especially with early results supporting its efficacy and safety in clinical trials.
OKYO's Commitment to Innovation
Underscoring its dedication, OKYO Pharma is actively conducting a Phase 2 trial for OK-101 as treatment for DED while also preparing to evaluate its effectiveness against NCP. Their continued research seeks to enhance life quality for individuals grappling with these chronic ocular conditions.
Contact Information for Inquiries
To learn more about OKYO Pharma and its ongoing trials, or for participation opportunities, interested parties are encouraged to reach out directly to:
OKYO Pharma Limited
Gary S. Jacob, Chief Executive Officer
Phone: 917-497-7560
Business Development & Investor Relations
Paul Spencer
Phone: +44 (0)20 7495 2379
Frequently Asked Questions
What is OKYO Pharma's primary focus?
OKYO Pharma primarily develops innovative therapies to treat neuropathic corneal pain and inflammatory dry eye disease.
What is the significance of the TFOS Conference?
The TFOS Conference is a major event that gathers experts in ocular health to discuss advancements, share research, and enhance collaborative solutions for eye conditions.
When will OKYO Pharma present at the conference?
Dr. Raj Patil will present on November 2, 2024, during a special session focused on their research findings.
Why are DED and NCP important conditions to address?
Both DED and NCP affect a vast number of individuals and significantly impact their daily lives, necessitating effective treatment options.
How can I get involved with OKYO's clinical trials?
For participation inquiries, prospective participants can reach out to OKYO Pharma directly through the provided contact information.
